NewAmsterdam Pharma Company N.V. beat EPS estimates 100% of the time across 1 reported quarters (1 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.48 | — | — | Miss |
| Q12026 FY2026 | $-0.46 | $-0.40 | +13.0% | Beat |
| 2026-02-25 | $-0.40 | — | — | Miss |
Back to NAMS overview · NAMS holders · NAMS KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.